

Anwar R Padhani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5186626/publications.pdf>

Version: 2024-02-01

290
papers

27,304
citations

5268

83
h-index

6654

156
g-index

295
all docs

295
docs citations

295
times ranked

20064
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | <scp>Whole-body magnetic resonance imaging</scp> for prostate cancer assessment: Current status and future directions. <i>Journal of Magnetic Resonance Imaging</i> , 2022, 55, 653-680. | 3.4 | 22 |
| 2 | Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings. <i>European Journal of Cancer</i> , 2022, 160, 24-60. | 2.8 | 12 |
| 3 | Application of diffusion-weighted whole-body MRI for response monitoring in multiple myeloma after chemotherapy: a systematic review and meta-analysis. <i>European Radiology</i> , 2022, 32, 2135-2148. | 4.5 | 3 |
| 4 | Balancing the benefits and harms of MRI-directed biopsy pathways. <i>European Radiology</i> , 2022, 32, 2326-2329. | 4.5 | 3 |
| 5 | Assessing the clinical performance of artificial intelligence software for prostate cancer detection on MRI. <i>European Radiology</i> , 2022, 32, 2221-2223. | 4.5 | 6 |
| 6 | Re: Targeted Prostate Biopsy: Umbra, Penumbra, and Value of Perilesional Sampling. <i>European Urology</i> , 2022, , . | 1.9 | 1 |
| 7 | Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. <i>European Urology</i> , 2022, 82, 115-141. | 1.9 | 51 |
| 8 | Audit of cancer yields after prostate MRI using both the PI-RADS version 2 and Likert scoring systems. <i>Clinical Radiology</i> , 2022, 77, 541-547. | 1.1 | 1 |
| 9 | Diagnostic Accuracy and Observer Agreement of the MRI Prostate Imaging for Recurrence Reporting Assessment Score. <i>Radiology</i> , 2022, 304, 342-350. | 7.3 | 21 |
| 10 | Diagnostic Performance of a Magnetic Resonance Imaging-directed Targeted plus Regional Biopsy Approach in Prostate Cancer Diagnosis: A Systematic Review and Meta-analysis. <i>European Urology Open Science</i> , 2022, 40, 95-103. | 0.4 | 18 |
| 11 | A systematic review and meta-analysis of the diagnostic accuracy of biparametric prostate MRI for prostate cancer in men at risk. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 596-611. | 3.9 | 58 |
| 12 | Contrast Medium or No Contrast Medium for Prostate Cancer Diagnosis. That Is the Question. <i>Journal of Magnetic Resonance Imaging</i> , 2021, 53, 13-22. | 3.4 | 16 |
| 13 | Measuring the Quality of Diagnostic Prostate Magnetic Resonance Imaging: A Urologist's Perspective. <i>European Urology</i> , 2021, 79, 440-441. | 1.9 | 15 |
| 14 | A multifaceted approach to quality in the MRI-directed biopsy pathway for prostate cancer diagnosis. <i>European Radiology</i> , 2021, 31, 4386-4389. | 4.5 | 17 |
| 15 | Risk-adapted biopsy decision based on prostate magnetic resonance imaging and prostate-specific antigen density for enhanced biopsy avoidance in first prostate cancer diagnostic evaluation. <i>BJU International</i> , 2021, 127, 175-178. | 2.5 | 43 |
| 16 | Certification in reporting multiparametric magnetic resonance imaging of the prostate: recommendations of a UK consensus meeting. <i>BJU International</i> , 2021, 127, 304-306. | 2.5 | 32 |
| 17 | PI-RADS Committee Position on MRI Without Contrast Medium in Biopsy-Naive Men With Suspected Prostate Cancer: Narrative Review. <i>American Journal of Roentgenology</i> , 2021, 216, 3-19. | 2.2 | 76 |
| 18 | Prostate Magnetic Resonance Imaging for Local Recurrence Reporting (PI-RR): International Consensus-based Guidelines on Multiparametric Magnetic Resonance Imaging for Prostate Cancer Recurrence after Radiation Therapy and Radical Prostatectomy. <i>European Urology Oncology</i> , 2021, 4, 868-876. | 5.4 | 72 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Introducing the Node Reporting and Data System 1.0 (Node-RADS): a concept for standardized assessment of lymph nodes in cancer. <i>European Radiology</i> , 2021, 31, 6116-6124. | 4.5 | 44 |
| 20 | Semi-Automated Segmentation of Bone Metastases from Whole-Body MRI: Reproducibility of Apparent Diffusion Coefficient Measurements. <i>Diagnostics</i> , 2021, 11, 499. | 2.6 | 6 |
| 21 | Population-Based Prostate Cancer Screening With Magnetic Resonance Imaging or Ultrasonography. <i>JAMA Oncology</i> , 2021, 7, 395. | 7.1 | 87 |
| 22 | Positron Emission Tomography and Whole-body Magnetic Resonance Imaging for Metastasis-directed Therapy in Hormone-sensitive Oligometastatic Prostate Cancer After Primary Radical Treatment: A Systematic Review. <i>European Urology Oncology</i> , 2021, 4, 714-730. | 5.4 | 16 |
| 23 | Magnetic Resonance Imaging for Tailoring the Need to Biopsy During Follow-up for Men on Active Surveillance for Prostate Cancer. <i>European Urology</i> , 2021, 80, 564-566. | 1.9 | 4 |
| 24 | Fast Magnetic Resonance Imaging as a Viable Method for Directing the Prostate Cancer Diagnostic Pathway. <i>European Urology Oncology</i> , 2021, 4, 863-865. | 5.4 | 1 |
| 25 | ESUR/ESUI position paper: developing artificial intelligence for precision diagnosis of prostate cancer using magnetic resonance imaging. <i>European Radiology</i> , 2021, 31, 9567-9578. | 4.5 | 34 |
| 26 | Effects of Sex and Age on Fat Fraction, Diffusion-Weighted Image Signal Intensity and Apparent Diffusion Coefficient in the Bone Marrow of Asymptomatic Individuals: A Cross-Sectional Whole-Body MRI Study. <i>Diagnostics</i> , 2021, 11, 913. | 2.6 | 8 |
| 27 | Oncologically Relevant Findings Reporting and Data System (ONCO-RADS): Guidelines for the Acquisition, Interpretation, and Reporting of Whole-Body MRI for Cancer Screening. <i>Radiology</i> , 2021, 299, 494-507. | 7.3 | 26 |
| 28 | Can Diagnostic Magnetic Resonance Imaging for Suspected Clinically Significant Prostate Cancer Predict Unfavorable Long-term Outcome for Diagnosed Men for Pretreatment Counseling?. <i>European Urology Oncology</i> , 2021, 4, 529-531. | 5.4 | 1 |
| 29 | Whole-body magnetic resonance imaging (WB-MRI) for cancer screening: recommendations for use. <i>Radiologia Medica</i> , 2021, 126, 1434-1450. | 7.7 | 36 |
| 30 | Fracture Risk in Men with Metastatic Prostate Cancer Treated With Radium-223. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e299-e305. | 1.9 | 6 |
| 31 | Multiparametric Magnetic Resonance Imaging for the Detection of Clinically Significant Prostate Cancer: What Urologists Need to Know. Part 1: Acquisition. <i>European Urology</i> , 2020, 77, 457-468. | 1.9 | 62 |
| 32 | Personalizing prostate cancer diagnosis with multivariate risk prediction tools: how should prostate MRI be incorporated?. <i>World Journal of Urology</i> , 2020, 38, 531-545. | 2.2 | 24 |
| 33 | Analysis of Magnetic Resonance Imaging-directed Biopsy Strategies for Changing the Paradigm of Prostate Cancer Diagnosis. <i>European Urology Oncology</i> , 2020, 3, 32-41. | 5.4 | 53 |
| 34 | Developments in MRI-targeted prostate biopsy. <i>Current Opinion in Urology</i> , 2020, 30, 1-8. | 1.8 | 10 |
| 35 | Multiparametric Magnetic Resonance Imaging for the Detection of Clinically Significant Prostate Cancer: What Urologists Need to Know. Part 3: Targeted Biopsy. <i>European Urology</i> , 2020, 77, 481-490. | 1.9 | 36 |
| 36 | Multiparametric Magnetic Resonance Imaging for the Detection of Clinically Significant Prostate Cancer: What Urologists Need to Know. Part 2: Interpretation. <i>European Urology</i> , 2020, 77, 469-480. | 1.9 | 59 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 37 | Comparison of Whole-Body MRI, CT, and Bone Scintigraphy for Response Evaluation of Cancer Therapeutics in Metastatic Breast Cancer to Bone. <i>Radiology</i> , 2020, 297, 622-629. | 7.3 | 24 |
| 38 | Re: Variability of the Positive Predictive Value of PI-RADS for Prostate MRI Across 26 Centers: Experience of the Society of Abdominal Radiology Prostate Cancer Disease-focused Panel. <i>European Urology</i> , 2020, 78, 633-636. | 1.9 | 9 |
| 39 | Bone metastases. <i>Nature Reviews Disease Primers</i> , 2020, 6, 83. | 30.5 | 246 |
| 40 | Diagnostic yields in patients with suspected prostate cancer undergoing MRI as the first-line investigation in routine practice. <i>Clinical Radiology</i> , 2020, 75, 950-956. | 1.1 | 10 |
| 41 | Rethinking prostate cancer screening: could MRI be an alternative screening test?. <i>Nature Reviews Urology</i> , 2020, 17, 526-539. | 3.8 | 19 |
| 42 | Whole-body magnetic resonance imaging (WB-MRI) reporting with the METastasis Reporting and Data System for Prostate Cancer (MET-RADS-P): inter-observer agreement between readers of different expertise levels. <i>Cancer Imaging</i> , 2020, 20, 77. | 2.8 | 11 |
| 43 | What's New for Clinical Whole-body MRI (WB-MRI) in the 21st Century. <i>British Journal of Radiology</i> , 2020, 93, 20200562. | 2.2 | 26 |
| 44 | Delivering Clinical impacts of the MRI diagnostic pathway in prostate cancer diagnosis. <i>Abdominal Radiology</i> , 2020, 45, 4012-4022. | 2.1 | 18 |
| 45 | ESUR/ESUI consensus statements on multi-parametric MRI for the detection of clinically significant prostate cancer: quality requirements for image acquisition, interpretation and radiologists' training. <i>European Radiology</i> , 2020, 30, 5404-5416. | 4.5 | 185 |
| 46 | Radiologists Should Integrate Clinical Risk Factors with MRI Findings for Meaningful Prostate Cancer Staging. <i>Radiology</i> , 2020, 296, 96-97. | 7.3 | 5 |
| 47 | Whole-body magnetic resonance imaging (WB-MRI) for cancer screening in asymptomatic subjects of the general population: review and recommendations. <i>Cancer Imaging</i> , 2020, 20, 34. | 2.8 | 27 |
| 48 | Platinum Opinion Interview: The Evidence Base for the Benefit of Magnetic Resonance Imaging-directed Prostate Cancer Diagnosis is Sound. <i>European Urology</i> , 2020, 78, 307-309. | 1.9 | 7 |
| 49 | Factors Influencing Variability in the Performance of Multiparametric Magnetic Resonance Imaging in Detecting Clinically Significant Prostate Cancer: A Systematic Literature Review. <i>European Urology Oncology</i> , 2020, 3, 145-167. | 5.4 | 75 |
| 50 | Focus on the Quality of Prostate Multiparametric Magnetic Resonance Imaging: Synopsis of the ESUR/ESUI Recommendations on Quality Assessment and Interpretation of Images and Radiologists' Training. <i>European Urology</i> , 2020, 78, 483-485. | 1.9 | 27 |
| 51 | Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2020, 38, 1963-1996. | 1.6 | 107 |
| 52 | Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. <i>European Urology</i> , 2020, 77, 508-547. | 1.9 | 278 |
| 53 | ESUR/ESUI consensus statements on multi-parametric MRI for the detection of clinically significant prostate cancer: quality requirements for image acquisition, interpretation and radiologists' training. , 2020, 30, 5404. | | 1 |
| 54 | Detection and Characterization of Musculoskeletal Cancer Using Whole-Body Magnetic Resonance Imaging. <i>Seminars in Musculoskeletal Radiology</i> , 2020, 24, 726-750. | 0.7 | 7 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 55 | Population-based prostate cancer screening using a prospective, blinded, paired screen-positive comparison of PSA and fast MRI: The IP1-PROSTAGRAM study.. Journal of Clinical Oncology, 2020, 38, 5513-5513. | 1.6 | 2 |
| 56 | Prostate Imaging-Reporting and Data System Steering Committee: PI-RADS v2 Status Update and Future Directions. European Urology, 2019, 75, 385-396. | 1.9 | 200 |
| 57 | Imaging Diagnosis and Follow-up of Advanced Prostate Cancer: Clinical Perspectives and State of the Art. Radiology, 2019, 292, 273-286. | 7.3 | 46 |
| 58 | Detecting Prostate Cancer with Deep Learning for MRI: A Small Step Forward. Radiology, 2019, 293, 618-619. | 7.3 | 24 |
| 59 | High Diagnostic Performance of Short Magnetic Resonance Imaging Protocols for Prostate Cancer Detection in Biopsy-naïve Men: The Next Step in Magnetic Resonance Imaging Accessibility. European Urology, 2019, 76, 574-581. | 1.9 | 114 |
| 60 | PI-RADS Steering Committee: The PI-RADS Multiparametric MRI and MRI-directed Biopsy Pathway. Radiology, 2019, 292, 464-474. | 7.3 | 162 |
| 61 | Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed non-small-cell lung cancer: the prospective Streamline L trial. Lancet Respiratory Medicine, 2019, 7, 523-532. | 10.7 | 50 |
| 62 | Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed colorectal cancer: the prospective Streamline C trial. The Lancet Gastroenterology and Hepatology, 2019, 4, 529-537. | 8.1 | 51 |
| 63 | Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. European Urology, 2019, 76, 340-351. | 1.9 | 1,270 |
| 64 | How clinical imaging can assess cancer biology. Insights Into Imaging, 2019, 10, 28. | 3.4 | 68 |
| 65 | Adding Colour to the Grey Zone of Advanced Prostate Cancer. European Urology Focus, 2019, 5, 123-124. | 3.1 | 5 |
| 66 | Guidelines for Acquisition, Interpretation, and Reporting of Whole-Body MRI in Myeloma: Myeloma Response Assessment and Diagnosis System (MY-RADS). Radiology, 2019, 291, 5-13. | 7.3 | 209 |
| 67 | A Single-Arm, Multicenter Validation Study of Prostate Cancer Localization and Aggressiveness With a Quantitative Multiparametric Magnetic Resonance Imaging Approach. Investigative Radiology, 2019, 54, 437-447. | 6.2 | 24 |
| 68 | Multiparametric Magnetic Resonance Imaging for Prostate Cancer Detection: What We See and What We Miss. European Urology, 2019, 75, 721-722. | 1.9 | 12 |
| 69 | Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study. European Urology, 2019, 75, 570-578. | 1.9 | 521 |
| 70 | Whole-body magnetic resonance imaging (WB-MRI) in oncology: recommendations and key uses. Radiologia Medica, 2019, 124, 218-233. | 7.7 | 52 |
| 71 | Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Annals of Oncology, 2019, 30, e3. | 1.2 | 16 |
| 72 | Whole-body MRI compared with standard pathways for staging metastatic disease in lung and colorectal cancer: the Streamline diagnostic accuracy studies. Health Technology Assessment, 2019, 23, 1-270. | 2.8 | 34 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 73 | Advanced Imaging Techniques in Evaluation of Colorectal Cancer. Radiographics, 2018, 38, 740-765. | 3.3 | 52 |
| 74 | National implementation of multi-parametric magnetic resonance imaging for prostate cancer detection – recommendations from a UK consensus meeting. BJU International, 2018, 122, 13-25. | 2.5 | 106 |
| 75 | Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. European Urology, 2018, 73, 178-211. | 1.9 | 488 |
| 76 | UK quantitative WB-DWI technical workgroup: consensus meeting recommendations on optimisation, quality control, processing and analysis of quantitative whole-body diffusion-weighted imaging for cancer. British Journal of Radiology, 2018, 91, 20170577. | 2.2 | 70 |
| 77 | Baseline Multiparametric MRI for Selection of Prostate Cancer Patients Suitable for Active Surveillance: Which Features Matter?. Clinical Genitourinary Cancer, 2018, 16, 155-163.e6. | 1.9 | 17 |
| 78 | Consensus on molecular imaging and theranostics in prostate cancer. Lancet Oncology, The, 2018, 19, e696-e708. | 10.7 | 90 |
| 79 | Whole-Body Magnetic Resonance Imaging in Oncology. Magnetic Resonance Imaging Clinics of North America, 2018, 26, 495-507. | 1.1 | 32 |
| 80 | Metastasis Reporting and Data System for Prostate Cancer in Practice. Magnetic Resonance Imaging Clinics of North America, 2018, 26, 527-542. | 1.1 | 8 |
| 81 | Can the completeness of radiological cancer staging reports be improved using proforma reporting? A prospective multicentre non-blinded interventional study across 21 centres in the UK. BMJ Open, 2018, 8, e018499. | 1.9 | 20 |
| 82 | Clinical Utility of Multiparametric Magnetic Resonance Imaging as the First-line Tool for Men with High Clinical Suspicion of Prostate Cancer. European Urology, 2018, 1, 208-214. | 5.4 | 24 |
| 83 | Patterns of disease progression in patients with local and metastatic breast cancer as evaluated by whole-body magnetic resonance imaging. Breast, 2018, 40, 82-84. | 2.2 | 3 |
| 84 | Radium-223: Disease response and fracture assessment by whole body diffusion-weighted MRI (WB-DWMRI) in metastatic castration resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2018, 36, 5024-5024. | 1.6 | 2 |
| 85 | Metastasis Reporting and Data System for Prostate Cancer: Practical Guidelines for Acquisition, Interpretation, and Reporting of Whole-body Magnetic Resonance Imaging-based Evaluations of Multiorgan Involvement in Advanced Prostate Cancer. European Urology, 2017, 71, 81-92. | 1.9 | 230 |
| 86 | Reporting Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer: The PRECISE Recommendations – A Report of a European School of Oncology Task Force. European Urology, 2017, 71, 648-655. | 1.9 | 190 |
| 87 | Splenic Enlargement and Bone Marrow Hyperplasia in Patients Receiving Trastuzumab-Emtansine for Metastatic Breast Cancer. Targeted Oncology, 2017, 12, 229-234. | 3.6 | 5 |
| 88 | Streamlining staging of lung and colorectal cancer with whole body MRI; study protocols for two multicentre, non-randomised, single-arm, prospective diagnostic accuracy studies (Streamline C and) Tj ETQq0 0 0 0 BT /Overlock 10 Tf | | |
| 89 | The addition of whole-body magnetic resonance imaging to body computerised tomography alters treatment decisions in patients with metastatic breast cancer. European Journal of Cancer, 2017, 77, 109-116. | 2.8 | 35 |
| 90 | One-Step Systemic Staging for Patients with Breast Cancer. , 2017, , 265-276. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 91 | Rationale for Modernising Imaging in Advanced Prostate Cancer. <i>European Urology Focus</i> , 2017, 3, 223-239. | 3.1 | 62 |
| 92 | Imaging biomarker roadmap for cancer studies. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 169-186. | 27.6 | 792 |
| 93 | Inter- and Intra-Observer Repeatability of Quantitative Whole-Body, Diffusion-Weighted Imaging (WBDWI) in Metastatic Bone Disease. <i>PLoS ONE</i> , 2016, 11, e0153840. | 2.5 | 40 |
| 94 | Reply to Erik Rud and Eduard Baco's Letter to the Editor re: Re: Jeffrey C. Weinreb, Jelle O. Barentsz, Peter L. Choyke, et al. PI-RADS Prostate Imaging â€“ Reporting and Data System: 2015, Version 2. <i>Eur Urol</i> 2016;69:16â€“40. <i>European Urology</i> , 2016, 70, e137-e138. | 1.9 | 22 |
| 95 | Advanced imaging of colorectal cancer: From anatomy to molecular imaging. <i>Insights Into Imaging</i> , 2016, 7, 285-309. | 3.4 | 18 |
| 96 | Radiogenomics Monitoring in Breast Cancer Identifies Metabolism and Immune Checkpoints as Early Actionable Mechanisms of Resistance to Anti-angiogenic Treatment. <i>EBioMedicine</i> , 2016, 10, 109-116. | 6.1 | 27 |
| 97 | Bone imaging in prostate cancer: the evolving roles of nuclear medicine and radiology. <i>Clinical and Translational Imaging</i> , 2016, 4, 439-447. | 2.1 | 56 |
| 98 | Diffusionâ€“weighted imaging outside the brain: Consensus statement from an ISMRMâ€“sponsored workshop. <i>Journal of Magnetic Resonance Imaging</i> , 2016, 44, 521-540. | 3.4 | 146 |
| 99 | Arterial input functions in dynamic contrast-enhanced magnetic resonance imaging: which model performs best when assessing breast cancer response?. <i>British Journal of Radiology</i> , 2016, 89, 20150961. | 2.2 | 13 |
| 100 | Whole body MRI (WBâ€“MRI) assessment of metastatic spread in prostate cancer: Therapeutic perspectives on targeted management of oligometastatic disease. <i>Prostate</i> , 2016, 76, 1024-1033. | 2.3 | 43 |
| 101 | Synopsis of the PI-RADS v2 Guidelines for Multiparametric Prostate Magnetic Resonance Imaging and Recommendations for Use. <i>European Urology</i> , 2016, 69, 41-49. | 1.9 | 454 |
| 102 | Therapy Monitoring with Functional and Molecular MR Imaging. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2016, 24, 261-288. | 1.1 | 28 |
| 103 | Magnetic Resonance Imaging Before Prostate Biopsy: Time to Talk. <i>European Urology</i> , 2016, 69, 1-3. | 1.9 | 21 |
| 104 | Finding Minimal Extraprostatic Disease: Who Cares?. <i>European Urology</i> , 2016, 70, 246-247. | 1.9 | 6 |
| 105 | Body diffusion kurtosis imaging: Basic principles, applications, and considerations for clinical practice. <i>Journal of Magnetic Resonance Imaging</i> , 2015, 42, 1190-1202. | 3.4 | 274 |
| 106 | Proton magnetic resonance spectroscopy in oncology: the fingerprints of cancer?. <i>Diagnostic and Interventional Radiology</i> , 2015, 22, 75-89. | 1.5 | 39 |
| 107 | Imaging of Tumor Angiogenesis for Radiologistsâ€“Part 1: Biological and Technical Basis. <i>Current Problems in Diagnostic Radiology</i> , 2015, 44, 407-424. | 1.4 | 45 |
| 108 | Imaging of Tumor Angiogenesis for Radiologistsâ€“Part 2: Clinical Utility. <i>Current Problems in Diagnostic Radiology</i> , 2015, 44, 425-436. | 1.4 | 15 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | Will Magnetic Resonance Imaging-guided Biopsy Replace Systematic Biopsy?. <i>European Urology Focus</i> , 2015, 1, 152-155. | 3.1 | 2 |
| 110 | Magnetic Resonance Imaging, Digital Mammography, and Sonography: Tumor Characteristics and Tumor Biology in Primary Setting. <i>Journal of the National Cancer Institute Monographs</i> , 2015, 2015, 15-20. | 2.1 | 5 |
| 111 | Robot-assisted Radical Prostatectomy: Multiparametric MR Imagingâ€‘directed Intraoperative Frozen-Section Analysis to Reduce the Rate of Positive Surgical Margins. <i>Radiology</i> , 2015, 274, 434-444. | 7.3 | 48 |
| 112 | Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. <i>Annals of Oncology</i> , 2015, 26, 1589-1604. | 1.2 | 279 |
| 113 | Assessing response to treatment of bone metastases from breast cancer: what should be the standard of care?. <i>Annals of Oncology</i> , 2015, 26, 1048-1057. | 1.2 | 58 |
| 114 | Phase I Study of Nintedanib Incorporating Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Patients With Advanced Solid Tumors. <i>Oncologist</i> , 2015, 20, 368-369. | 3.7 | 5 |
| 115 | Assessment of Treatment Response by Total Tumor Volume and Global Apparent Diffusion Coefficient Using Diffusion-Weighted MRI in Patients with Metastatic Bone Disease: A Feasibility Study. <i>PLoS ONE</i> , 2014, 9, e91779. | 2.5 | 104 |
| 116 | New Therapies and Functional-Molecular Imaging. , 2014, , 77-96. | | 0 |
| 117 | Optimal source distribution for focal boosts using high dose rate (HDR) brachytherapy alone in prostate cancer. <i>Radiotherapy and Oncology</i> , 2014, 113, 121-125. | 0.6 | 14 |
| 118 | Apparent diffusion coefficient measurements as very early predictive markers of response to chemotherapy in hepatic metastasis: A preliminary investigation of reproducibility and diagnostic value. <i>Journal of Magnetic Resonance Imaging</i> , 2014, 40, 448-456. | 3.4 | 25 |
| 119 | Whole-body MRI and diffusion MRI. <i>Cancer Imaging</i> , 2014, 14, . | 2.8 | 2 |
| 120 | Therapy monitoring of skeletal metastases with whole-body diffusion MRI. <i>Journal of Magnetic Resonance Imaging</i> , 2014, 39, 1049-1078. | 3.4 | 99 |
| 121 | Assessing response in breast cancer with dynamic contrast-enhanced magnetic resonance imaging: Are signal intensityâ€‘time curves adequate?. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 335-343. | 2.5 | 28 |
| 122 | Whole-body diffusion-weighted imaging: is it all we need for detecting metastases in melanoma patients?. <i>European Radiology</i> , 2013, 23, 3466-3476. | 4.5 | 39 |
| 123 | Prostate MRI: Who, when, and how? Report from a UK consensus meeting. <i>Clinical Radiology</i> , 2013, 68, 1016-1023. | 1.1 | 79 |
| 124 | Clinical applications of multiparametric MRI within the prostate cancer diagnostic pathway. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 281-284. | 1.6 | 32 |
| 125 | Prostate cancer: ESMO Consensus Conference Guidelines 2012. <i>Annals of Oncology</i> , 2013, 24, 1141-1162. | 1.2 | 137 |
| 126 | Scoring systems used for the interpretation and reporting of multiparametric MRI for prostate cancer detection, localization, and characterization: could standardization lead to improved utilization of imaging within the diagnostic pathway?. <i>Journal of Magnetic Resonance Imaging</i> , 2013, 37, 48-58. | 3.4 | 119 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 127 | CT Perfusion in Oncologic Imaging: A Useful Tool?. American Journal of Roentgenology, 2013, 200, 8-19. | 2.2 | 146 |
| 128 | The diagnostic accuracy and cost-effectiveness of magnetic resonance spectroscopy and enhanced magnetic resonance imaging techniques in aiding the localisation of prostate abnormalities for biopsy: a systematic review and economic evaluation. Health Technology Assessment, 2013, 17, vii-xix, 1-281. | 2.8 | 102 |
| 129 | Assessing the Relation Between Bone Marrow Signal Intensity and Apparent Diffusion Coefficient in Diffusion-Weighted MRI. American Journal of Roentgenology, 2013, 200, 163-170. | 2.2 | 137 |
| 130 | Phase I Trial of Combretastatin A4 Phosphate (CA4P) in Combination with Bevacizumab in Patients with Advanced Cancer. Clinical Cancer Research, 2012, 18, 3428-3439. | 7.0 | 158 |
| 131 | Phase Ib trial of radiotherapy in combination with combretastatin-A4-phosphate in patients with non-small-cell lung cancer, prostate adenocarcinoma, and squamous cell carcinoma of the head and neck. Annals of Oncology, 2012, 23, 231-237. | 1.2 | 68 |
| 132 | Phase I Clinical and Pharmacokinetic Evaluation of the Vascular-Disrupting Agent OXi4503 in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2012, 18, 1415-1425. | 7.0 | 69 |
| 133 | Whole-Body Diffusion-Weighted MRI: Tips, Tricks, and Pitfalls. American Journal of Roentgenology, 2012, 199, 252-262. | 2.2 | 158 |
| 134 | Tumor response assessments with diffusion and perfusion MRI. Journal of Magnetic Resonance Imaging, 2012, 35, 745-763. | 3.4 | 150 |
| 135 | Diffusion tensor imaging of the anal canal at 3 tesla: Feasibility and reproducibility of anisotropy measures. Journal of Magnetic Resonance Imaging, 2012, 35, 820-826. | 3.4 | 14 |
| 136 | Imaging vascular function for early stage clinical trials using dynamic contrast-enhanced magnetic resonance imaging. European Radiology, 2012, 22, 1451-1464. | 4.5 | 138 |
| 137 | Diffusion-weighted MRI compared to FDG PET-CT in the staging and response assessment of Hodgkin lymphoma. British Journal of Haematology, 2012, 156, 557-557. | 2.5 | 8 |
| 138 | Diffusion MR Imaging for Monitoring of Treatment Response. Magnetic Resonance Imaging Clinics of North America, 2011, 19, 181-209. | 1.1 | 123 |
| 139 | Novel Oncologic Drugs: What They Do and How They Affect Images. Radiographics, 2011, 31, 2059-2091. | 3.3 | 71 |
| 140 | Integrating multiparametric prostate MRI into clinical practice. Cancer Imaging, 2011, 11, S27-S37. | 2.8 | 24 |
| 141 | Bony metastases: assessing response to therapy with whole-body diffusion MRI. Cancer Imaging, 2011, 11, S129-S154. | 2.8 | 63 |
| 142 | Clinical utility of diffusion-weighted magnetic resonance imaging in prostate cancer. BJU International, 2011, 108, 1716-1722. | 2.5 | 39 |
| 143 | Diffusion Magnetic Resonance Imaging in Cancer Patient Management. Seminars in Radiation Oncology, 2011, 21, 119-140. | 2.2 | 47 |
| 144 | Magnetic Resonance Imaging for the Detection, Localisation, and Characterisation of Prostate Cancer: Recommendations from a European Consensus Meeting. European Urology, 2011, 59, 477-494. | 1.9 | 642 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 145 | Vascular characterisation of triple negative breast carcinomas using dynamic MRI. <i>European Radiology</i> , 2011, 21, 1364-1373. | 4.5 | 73 |
| 146 | Diffusion-weighted imaging (DWI) in musculoskeletal MRI: a critical review. <i>Skeletal Radiology</i> , 2011, 40, 665-681. | 2.0 | 219 |
| 147 | Antivascular Effects of Neoadjuvant Androgen Deprivation for Prostate Cancer: An In Vivo Human Study Using Susceptibility and Relaxivity Dynamic MRI. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 721-727. | 0.8 | 54 |
| 148 | Use of Dynamic Contrast-enhanced MR Imaging to Predict Survival in Patients with Primary Breast Cancer Undergoing Neoadjuvant Chemotherapy. <i>Radiology</i> , 2011, 260, 68-78. | 7.3 | 95 |
| 149 | Whole-Body Diffusion-weighted MR Imaging in Cancer: Current Status and Research Directions. <i>Radiology</i> , 2011, 261, 700-718. | 7.3 | 293 |
| 150 | Dynamic Contrast-Enhanced Magnetic Resonance Imaging and Blood Oxygenation Level-Dependent Magnetic Resonance Imaging for the Assessment of Changes in Tumor Biology With Treatment. <i>Journal of the National Cancer Institute Monographs</i> , 2011, 2011, 103-107. | 2.1 | 32 |
| 151 | Assessing Early Therapeutic Response to Bevacizumab in Primary Breast Cancer Using Magnetic Resonance Imaging and Gene Expression Profiles. <i>Journal of the National Cancer Institute Monographs</i> , 2011, 2011, 71-74. | 2.1 | 42 |
| 152 | Diffusion-weighted MRI of female pelvic tumors. , 2010, , 119-143. | | 2 |
| 153 | Perfusion MRI in the early clinical development of antivascular drugs: decorations or decision making tools?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 164-182. | 6.4 | 64 |
| 154 | Diffusion-weighted (DW) and dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) for monitoring anticancer therapy. <i>Targeted Oncology</i> , 2010, 5, 39-52. | 3.6 | 95 |
| 155 | Reproducibility and correlation between quantitative and semiquantitative dynamic and intrinsic susceptibility-weighted MRI parameters in the benign and malignant human prostate. <i>Journal of Magnetic Resonance Imaging</i> , 2010, 32, 155-164. | 3.4 | 47 |
| 156 | Magnetic Resonance Imaging Assessment of Squamous Cell Carcinoma of the Anal Canal Before and After Chemoradiation: Can MRI Predict for Eventual Clinical Outcome?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 715-721. | 0.8 | 62 |
| 157 | Multiparametric Imaging of Tumor Response to Therapy. <i>Radiology</i> , 2010, 256, 348-364. | 7.3 | 201 |
| 158 | The Role of Functional Imaging in Colorectal Cancer. <i>American Journal of Roentgenology</i> , 2010, 195, 54-66. | 2.2 | 56 |
| 159 | Primary Human Breast Adenocarcinoma: Imaging and Histologic Correlates of Intrinsic Susceptibility-weighted MR Imaging before and during Chemotherapy. <i>Radiology</i> , 2010, 257, 643-652. | 7.3 | 52 |
| 160 | Science to Practice: What Does MR Oxygenation Imaging Tell Us about Human Breast Cancer Hypoxia?. <i>Radiology</i> , 2010, 254, 1-3. | 7.3 | 35 |
| 161 | Functional Magnetic Resonance Imaging of the Liver: Parametric Assessments Beyond Morphology. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2010, 18, 565-585. | 1.1 | 10 |
| 162 | MRI to Assess Vascular Disruptive Agents. , 2010, , 137-163. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 163 | Carbogen breathing increases prostate cancer oxygenation: a translational MRI study in murine xenografts and humans. <i>British Journal of Cancer</i> , 2009, 100, 644-648. | 6.4 | 56 |
| 164 | A Phase I Trial of Radioimmunotherapy with 131I-A5B7 Anti-CEA Antibody in Combination with Combretastatin-A4-Phosphate in Advanced Gastrointestinal Carcinomas. <i>Clinical Cancer Research</i> , 2009, 15, 4484-4492. | 7.0 | 68 |
| 165 | Unresectable Hepatocellular Carcinoma: Serial Early Vascular and Cellular Changes after Transarterial Chemoembolization. <i>Radiology</i> , 2009, 250, 324-326. | 7.3 | 5 |
| 166 | Quantitative Analysis of Dynamic Contrast-Enhanced MR Images Based on Bayesian P-Splines. <i>IEEE Transactions on Medical Imaging</i> , 2009, 28, 789-798. | 8.9 | 35 |
| 167 | A Bayesian hierarchical model for the analysis of a longitudinal dynamic contrast-enhanced MRI oncology study. <i>Magnetic Resonance in Medicine</i> , 2009, 61, 163-174. | 3.0 | 29 |
| 168 | Study of tumor blood perfusion and its variation due to vascular normalization by anti-angiogenic therapy based on 3D angiogenic microvasculature. <i>Journal of Biomechanics</i> , 2009, 42, 712-721. | 2.1 | 64 |
| 169 | Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial. <i>European Radiology</i> , 2009, 19, 2728-2738. | 4.5 | 151 |
| 170 | Diffusion-weighted MR Imaging of Female Pelvic Tumors: A Pictorial Review. <i>Radiographics</i> , 2009, 29, 759-774. | 3.3 | 165 |
| 171 | Dynamic optical breast imaging: A novel technique to detect and characterize tumor vessels. <i>European Journal of Radiology</i> , 2009, 69, 43-49. | 2.6 | 31 |
| 172 | Diffusion-Weighted Magnetic Resonance Imaging as a Cancer Biomarker: Consensus and Recommendations. <i>Neoplasia</i> , 2009, 11, 102-125. | 5.3 | 1,703 |
| 173 | Diffusion-Weighted Imaging. , 2009, , 685-706. | | 0 |
| 174 | Coupled modeling of blood perfusion in intravascular, interstitial spaces in tumor microvasculature. <i>Journal of Biomechanics</i> , 2008, 41, 996-1004. | 2.1 | 31 |
| 175 | Quantitative mapping of hepatic perfusion index using MR imaging: a potential reproducible tool for assessing tumour response to treatment with the antiangiogenic compound BIBF 1120, a potent triple angiokinase inhibitor. <i>European Radiology</i> , 2008, 18, 1414-1421. | 4.5 | 39 |
| 176 | Technology Insight: water diffusion MRI—a potential new biomarker of response to cancer therapy. <i>Nature Clinical Practice Oncology</i> , 2008, 5, 220-233. | 4.3 | 326 |
| 177 | Early Changes in Functional Dynamic Magnetic Resonance Imaging Predict for Pathologic Response to Neoadjuvant Chemotherapy in Primary Breast Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 6580-6589. | 7.0 | 250 |
| 178 | Numerical Study of Tumour Blood Perfusion Based on 3D Tumour Angiogenic Microvasculatures. , 2008, , . | | 0 |
| 179 | Simulation of Microcirculation in Solid Tumors. , 2007, , . | | 2 |
| 180 | ¹⁸Fluorodeoxyglucose Positron Emission Tomography in the Prediction of Relapse in Patients With High-Risk, Clinical Stage I Nonseminomatous Germ Cell Tumors: Preliminary Report of MRC Trial TE22—the NCRITestis Tumour Clinical Study Group. <i>Journal of Clinical Oncology</i> , 2007, 25, 3090-3095. | 1.6 | 122 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 181 | Rectal Carcinoma: MRI with Histologic Correlation Before and After Chemoradiation Therapy. American Journal of Roentgenology, 2007, 188, 442-451. | 2.2 | 123 |
| 182 | Dynamic contrast enhanced MRI in prostate cancer. European Journal of Radiology, 2007, 63, 335-350. | 2.6 | 196 |
| 183 | Functional imaging of colorectal cancer angiogenesis. Lancet Oncology, The, 2007, 8, 245-255. | 10.7 | 92 |
| 184 | Dynamic MRI for imaging tumor microvasculature: Comparison of susceptibility and relaxivity techniques in pelvic tumors. Journal of Magnetic Resonance Imaging, 2007, 25, 796-805. | 3.4 | 48 |
| 185 | Acute tumor vascular effects following fractionated radiotherapy in human lung cancer: In vivo whole tumor assessment using volumetric perfusion computed tomography. International Journal of Radiation Oncology Biology Physics, 2007, 67, 417-424. | 0.8 | 78 |
| 186 | Tumor Antivascular Effects of Radiotherapy Combined with Combretastatin A4 Phosphate in Human Non-Small-Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2007, 67, 1375-1380. | 0.8 | 73 |
| 187 | Imaging oxygenation of human tumours. European Radiology, 2007, 17, 861-872. | 4.5 | 304 |
| 188 | Numerical simulation of blood flow and interstitial fluid pressure in solid tumor microcirculation based on tumor-induced angiogenesis. Acta Mechanica Sinica/Lixue Xuebao, 2007, 23, 477-483. | 3.4 | 19 |
| 189 | Simulation of Blood Perfusion in Tumour Microvasculature. , 2007, , . | | 0 |
| 190 | Hypoxia: Importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. International Journal of Radiation Biology, 2006, 82, 699-757. | 1.8 | 561 |
| 191 | Bayesian Methods for Pharmacokinetic Models in Dynamic Contrast-Enhanced Magnetic Resonance Imaging. IEEE Transactions on Medical Imaging, 2006, 25, 1627-1636. | 8.9 | 80 |
| 192 | Diffusion-weighted MRI: a new functional clinical technique for tumour imaging. British Journal of Radiology, 2006, 79, 633-635. | 2.2 | 142 |
| 193 | USPIO ? enhanced rectal cancer specimen MRI: how well does it correlate with node identification at histopathology?. Colorectal Disease, 2006, 8, 721-721. | 1.4 | 4 |
| 194 | A test of performance of breast MRI interpretation in a multicentre screening study. Magnetic Resonance Imaging, 2006, 24, 917-929. | 1.8 | 16 |
| 195 | Imaging tumor angiogenesis: functional assessment using MDCT or MRI?. Abdominal Imaging, 2006, 31, 194-199. | 2.0 | 70 |
| 196 | Dynamic contrast-enhanced magnetic resonance imaging is a poor measure of rectal cancer angiogenesis. British Journal of Surgery, 2006, 93, 992-1000. | 0.3 | 65 |
| 197 | Inter- and intraobserver variability in the evaluation of dynamic breast cancer MRI. Journal of Magnetic Resonance Imaging, 2006, 24, 1316-1325. | 3.4 | 33 |
| 198 | Magnetic Resonance Imaging Workbench: Analysis and Visualization of Dynamic Contrast-enhanced MR Imaging Data. Radiographics, 2006, 26, 621-632. | 3.3 | 82 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 199 | Evaluation of a Prospective Scoring System Designed for a Multicenter Breast MR Imaging Screening Study. <i>Radiology</i> , 2006, 239, 677-685. | 7.3 | 29 |
| 200 | Quantitative Assessment of Lung Cancer Perfusion Using MDCT: Does Measurement Reproducibility Improve with Greater Tumor Volume Coverage?. <i>American Journal of Roentgenology</i> , 2006, 187, 1079-1084. | 2.2 | 72 |
| 201 | Prediction of Clinicopathologic Response of Breast Cancer to Primary Chemotherapy at Contrast-enhanced MR Imaging: Initial Clinical Results. <i>Radiology</i> , 2006, 239, 361-374. | 7.3 | 224 |
| 202 | Lung Cancer Perfusion at Multi-â€œDetector Row CT: Reproducibility of Whole Tumor Quantitative Measurements. <i>Radiology</i> , 2006, 239, 547-553. | 7.3 | 132 |
| 203 | The relationship of the neo-angiogenic marker, endoglin, with response to neoadjuvant chemotherapy in breast cancer. <i>British Journal of Cancer</i> , 2006, 95, 1683-1688. | 6.4 | 41 |
| 204 | Cost-effectiveness of screening with contrast enhanced magnetic resonance imaging vs X-ray mammography of women at a high familial risk of breast cancer. <i>British Journal of Cancer</i> , 2006, 95, 801-810. | 6.4 | 113 |
| 205 | A phase I study of BIBF 1120, an orally active triple angiokinase inhibitor (VEGFR, PDGFR, FGFR) given continuously to patients with advanced solid tumours, incorporating dynamic contrast enhanced magnetic resonance imaging (DCE-MRI). <i>Journal of Clinical Oncology</i> , 2006, 24, 3015-3015. | 1.6 | 14 |
| 206 | PET imaging of tumour hypoxia. <i>Cancer Imaging</i> , 2006, 6, 1-1. | 2.8 | 15 |
| 207 | Dynamic Contrast-Enhanced MRI of Prostate Cancer. , 2005, , 191-213. | | 2 |
| 208 | Dynamic Magnetic Resonance Imaging in Breast Cancer. , 2005, , 145-173. | | 2 |
| 209 | Dynamic contrast-enhanced magnetic resonance imaging of radiation therapy-induced microcirculation changes in rectal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 63, 1309-1315. | 0.8 | 128 |
| 210 | Tumour staging using magnetic resonance imaging in clinically localised prostate cancer: relationship to biochemical outcome after neo-adjuvant androgen deprivation and radical radiotherapy. <i>Clinical Oncology</i> , 2005, 17, 167-171. | 1.4 | 16 |
| 211 | The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. <i>British Journal of Cancer</i> , 2005, 92, 1599-1610. | 6.4 | 487 |
| 212 | Surgical restraint in the management of liver trauma. <i>British Journal of Surgery</i> , 2005, 78, 1071-1075. | 0.3 | 31 |
| 213 | Antivascular cancer treatments: functional assessments by dynamic contrast-enhanced magnetic resonance imaging. <i>Abdominal Imaging</i> , 2005, 30, 325-342. | 2.0 | 116 |
| 214 | Where are we with imaging oxygenation in human tumours?. <i>Cancer Imaging</i> , 2005, 5, 128-130. | 2.8 | 40 |
| 215 | Imaging Tumour Angiogenesis. <i>Cancer Imaging</i> , 2005, 5, 131-138. | 2.8 | 65 |
| 216 | Imaging breast cancer response during neoadjuvant systemic therapy. <i>Expert Review of Anticancer Therapy</i> , 2005, 5, 893-905. | 2.4 | 23 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 217 | MRI in the detection and management of breast cancer. Expert Review of Anticancer Therapy, 2005, 5, 239-252. | 2.4 | 19 |
| 218 | Reading Protocol for Dynamic Contrast-enhanced MR Images of the Breast: Sensitivity and Specificity Analysis. Radiology, 2005, 236, 779-788. | 7.3 | 99 |
| 219 | Statistical Analysis of Pharmacokinetic Models in Dynamic Contrast-Enhanced Magnetic Resonance Imaging. Lecture Notes in Computer Science, 2005, 8, 886-893. | 1.3 | 11 |
| 220 | Angiogenesis imaging in the management of prostate cancer. Nature Reviews Urology, 2005, 2, 596-607. | 1.4 | 57 |
| 221 | Effects of platinum/taxane based chemotherapy on acute perfusion in human pelvic tumours measured by dynamic MRI. British Journal of Cancer, 2005, 93, 979-985. | 6.4 | 30 |
| 222 | Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet, The, 2005, 365, 1769-1778. | 13.7 | 927 |
| 223 | Dynamic magnetic resonance imaging of tumor perfusion. IEEE Engineering in Medicine and Biology Magazine, 2004, 23, 65-83. | 0.8 | 155 |
| 224 | Perfusion MR Imaging of Extracranial Tumor Angiogenesis. Topics in Magnetic Resonance Imaging, 2004, 15, 41-57. | 1.2 | 63 |
| 225 | Does vascular imaging with MRI predict response to neoadjuvant chemotherapy in primary breast cancer?. Journal of Clinical Oncology, 2004, 22, 582-582. | 1.6 | 8 |
| 226 | Dynamic MRI of breast hardness following radiation treatment. Journal of Magnetic Resonance Imaging, 2003, 17, 427-434. | 3.4 | 16 |
| 227 | Assessment of antiangiogenic and antivascular therapeutics using MRI: recommendations for appropriate methodology for clinical trials. British Journal of Radiology, 2003, 76, S87-S91. | 2.2 | 121 |
| 228 | The pathway study: results of a pilot feasibility study in patients suspected of having lung carcinoma investigated in a conventional chest clinic setting compared to a centralised two-stop pathway. Lung Cancer, 2003, 42, 283-290. | 2.0 | 77 |
| 229 | Combretastatin A4 Phosphate Has Tumor Antivascular Activity in Rat and Man as Demonstrated by Dynamic Magnetic Resonance Imaging. Journal of Clinical Oncology, 2003, 21, 2831-2842. | 1.6 | 328 |
| 230 | MRI for assessing antivascular cancer treatments. British Journal of Radiology, 2003, 76, S60-S80. | 2.2 | 131 |
| 231 | Why do we need more accurate intraprostatic localization of cancer?. British Journal of Radiology, 2003, 76, 585-586. | 2.2 | 9 |
| 232 | Recent advances in oncological imaging. Clinical Medicine, 2003, 3, 318-322. | 1.9 | 2 |
| 233 | Effects of 5,6-Dimethylxanthenone-4-Acetic Acid on Human Tumor Microcirculation Assessed by Dynamic Contrast-Enhanced Magnetic Resonance Imaging. Journal of Clinical Oncology, 2002, 20, 3826-3840. | 1.6 | 150 |
| 234 | A multicentre phase II trial of primary chemotherapy with cisplatin and protracted venous infusion 5-fluorouracil followed by chemoradiation in patients with carcinoma of the oesophagus. Annals of Oncology, 2002, 13, 1763-1770. | 1.2 | 8 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 235 | Magnetic resonance imaging of induration in the irradiated breast. <i>Radiotherapy and Oncology</i> , 2002, 64, 157-162. | 0.6 | 18 |
| 236 | Diffusion MRI for prediction of response of rectal cancer to chemoradiation. <i>Lancet, The</i> , 2002, 360, 307-308. | 13.7 | 437 |
| 237 | Initial observations on the effect of irradiation on the liver-specific uptake of Levovist. <i>European Journal of Radiology</i> , 2002, 41, 192-199. | 2.6 | 32 |
| 238 | Functional MRI for anticancer therapy assessment. <i>European Journal of Cancer</i> , 2002, 38, 2116-2127. | 2.8 | 96 |
| 239 | Dynamic contrast-enhanced MRI in clinical oncology: Current status and future directions. <i>Journal of Magnetic Resonance Imaging</i> , 2002, 16, 407-422. | 3.4 | 415 |
| 240 | Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: comparison of quantitative and semi-quantitative analysis. <i>NMR in Biomedicine</i> , 2002, 15, 132-142. | 2.8 | 323 |
| 241 | Reproducibility of quantitative dynamic MRI of normal human tissues. <i>NMR in Biomedicine</i> , 2002, 15, 143-153. | 2.8 | 183 |
| 242 | Applications of sliding window reconstruction with cartesian sampling for dynamic contrast enhanced MRI. <i>NMR in Biomedicine</i> , 2002, 15, 174-183. | 2.8 | 68 |
| 243 | Assessing changes in tumour vascular function using dynamic contrast-enhanced magnetic resonance imaging. <i>NMR in Biomedicine</i> , 2002, 15, 154-163. | 2.8 | 250 |
| 244 | Non-invasive methods of assessing angiogenesis and their value in predicting response to treatment in colorectal cancer. <i>British Journal of Surgery</i> , 2002, 88, 1628-1636. | 0.3 | 212 |
| 245 | Clinical and immunological assessment of <i>Mycobacterium vaccae</i> (SRL172) with chemotherapy in patients with malignant mesothelioma. <i>British Journal of Cancer</i> , 2002, 86, 336-341. | 6.4 | 20 |
| 246 | Dynamic Contrast-enhanced MRI Studies in Oncology with an Emphasis on Quantification, Validation and Human Studies. <i>Clinical Radiology</i> , 2001, 56, 607-620. | 1.1 | 220 |
| 247 | BOLD MRI of human tumor oxygenation during carbogen breathing. <i>Journal of Magnetic Resonance Imaging</i> , 2001, 14, 156-163. | 3.4 | 175 |
| 248 | Problem in diagnostic imaging: Mediastinal venous anomalies. <i>Clinical Anatomy</i> , 2001, 14, 218-226. | 2.7 | 6 |
| 249 | The prevalence of avascular necrosis in patients treated with chemotherapy for testicular tumours. <i>British Journal of Cancer</i> , 2001, 85, 1624-1626. | 6.4 | 31 |
| 250 | Challenges for imaging angiogenesis. <i>British Journal of Radiology</i> , 2001, 74, 886-890. | 2.2 | 60 |
| 251 | The RECIST criteria: implications for diagnostic radiologists. <i>British Journal of Radiology</i> , 2001, 74, 983-986. | 2.2 | 238 |
| 252 | Use of first line bronchoalveolar lavage in the immunosuppressed oncology patient. <i>Bone Marrow Transplantation</i> , 2001, 27, 967-971. | 2.4 | 49 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 253 | Effects of Androgen Deprivation on Prostatic Morphology and Vascular Permeability Evaluated with MR Imaging. <i>Radiology</i> , 2001, 218, 365-374. | 7.3 | 143 |
| 254 | Dynamic contrast-enhanced MR imaging. <i>Cancer Imaging</i> , 2000, 1, 52-63. | 2.8 | 7 |
| 255 | Reduction of small and large bowel irradiation using an optimized intensity-modulated pelvic radiotherapy technique in patients with prostate cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2000, 48, 649-656. | 0.8 | 219 |
| 256 | Magnetic resonance imaging screening in women at genetic risk of breast cancer: imaging and analysis protocol for the UK multicentre study. <i>Magnetic Resonance Imaging</i> , 2000, 18, 765-776. | 1.8 | 104 |
| 257 | FDG-PET in the prediction of survival of patients with cancer of the pancreas: a pilot study. <i>British Journal of Cancer</i> , 2000, 83, 287-293. | 6.4 | 111 |
| 258 | Symptomatic Brachial Plexopathy following Treatment for Breast Cancer: Utility of MR Imaging with Surface-Coil Techniques. <i>Radiology</i> , 2000, 214, 837-842. | 7.3 | 79 |
| 259 | Commentary. Are current tumour response criteria relevant for the 21st century?. <i>British Journal of Radiology</i> , 2000, 73, 1031-1033. | 2.2 | 33 |
| 260 | Dynamic Contrast Enhanced MRI of Prostate Cancer: Correlation with Morphology and Tumour Stage, Histological Grade and PSA. <i>Clinical Radiology</i> , 2000, 55, 99-109. | 1.1 | 320 |
| 261 | In vivo monitoring of tumor angiogenesis with MR imaging. <i>Academic Radiology</i> , 2000, 7, 812-823. | 2.5 | 117 |
| 262 | Comparative efficacy of and sequence choice for two oral contrast agents used during MR imaging.. <i>American Journal of Roentgenology</i> , 1999, 173, 173-178. | 2.2 | 23 |
| 263 | Comparison of MRI with CT for the radiotherapy planning of prostate cancer: a feasibility study.. <i>British Journal of Radiology</i> , 1999, 72, 590-597. | 2.2 | 81 |
| 264 | Dynamic contrast-enhanced MRI studies in human tumours.. <i>British Journal of Radiology</i> , 1999, 72, 427-431. | 2.2 | 30 |
| 265 | Advances in imaging of colorectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , 1999, 30, 189-199. | 4.4 | 6 |
| 266 | Evaluating the effect of rectal distension and rectal movement on prostate gland position using cine MRI. <i>International Journal of Radiation Oncology Biology Physics</i> , 1999, 44, 525-533. | 0.8 | 262 |
| 267 | Beware the stronger magnet.. <i>American Journal of Roentgenology</i> , 1999, 173, 243-243. | 2.2 | 0 |
| 268 | Spiral CT: thoracic applications. <i>European Journal of Radiology</i> , 1998, 28, 2-17. | 2.6 | 11 |
| 269 | Magnetic resonance imaging of prostate cancer: Comparison of image quality using endorectal and pelvic phased array coils. <i>Clinical Radiology</i> , 1998, 53, 673-681. | 1.1 | 68 |
| 270 | Metastatic cardiac osteosarcoma-imaging features.. <i>British Journal of Radiology</i> , 1998, 71, 336-339. | 2.2 | 9 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 271 | MRIW: parametric analysis software for contrast-enhanced dynamic MR imaging in cancer.. Radiographics, 1998, 18, 497-506. | 3.3 | 55 |
| 272 | Mediastinal venous anomalies: potential pitfalls in cancer diagnosis.. British Journal of Radiology, 1998, 71, 792-798. | 2.2 | 13 |
| 273 | Radiation induced liver injury detected by particulate reticuloendothelial contrast agent.. British Journal of Radiology, 1998, 71, 1089-1092. | 2.2 | 10 |
| 274 | Magnetic resonance imaging (MRI): considerations and applications in radiotherapy treatment planning. Radiotherapy and Oncology, 1997, 42, 1-15. | 0.6 | 266 |
| 275 | A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. Annals of Oncology, 1997, 8, 995-1001. | 1.2 | 121 |
| 276 | Evaluation by magnetic resonance imaging of the inferior vena cava in patients with non-seminomatous germ cell tumours of the testis metastatic to the retroperitoneum. BJU International, 1997, 79, 942-951. | 2.5 | 18 |
| 277 | Probing tumor microvasculature by measurement, analysis and display of contrast agent uptake kinetics. Journal of Magnetic Resonance Imaging, 1997, 7, 564-574. | 3.4 | 191 |
| 278 | Problem in diagnostic imaging: Behind the left renal vein. , 1997, 10, 349-352. | | 7 |
| 279 | The Value of Immediate Cytologic Evaluation for Needle Aspiration Lung Biopsy. Investigative Radiology, 1997, 32, 453-458. | 6.2 | 30 |
| 280 | Pulmonary sarcoidosis mimicking cryptogenic fibrosing alveolitis on CT. Clinical Radiology, 1996, 51, 807-810. | 1.1 | 71 |
| 281 | Phrenic artery injuryâ€”a rare complication of percutaneous needle lung biopsy. British Journal of Radiology, 1996, 69, 356-358. | 2.2 | 4 |
| 282 | CT Features of Pulmonary Nocardiosis. Journal of Computer Assisted Tomography, 1995, 19, 726-732. | 0.9 | 45 |
| 283 | Multiplanar display of spiral CT data of the pulmonary hila in patients with lung cancer. Clinical Imaging, 1995, 19, 252-257. | 1.5 | 16 |
| 284 | Eye and testicular pain after administration of gadopentetate dimeglumine.. American Journal of Roentgenology, 1995, 165, 484-485. | 2.2 | 2 |
| 285 | Squamous oesophageal cancer can be downstaged using protracted venous infusion of 5-fluorouracil with epirubicin and cisplatin (ECF). European Journal of Cancer, 1995, 31, 2209-2214. | 2.8 | 18 |
| 286 | The value of immediate cytological evaluation for needle aspiration lung biopsy. Clinical Radiology, 1995, 50, 350-351. | 1.1 | 4 |
| 287 | Computed tomography in abdominal trauma: an audit of usage and image quality. British Journal of Radiology, 1992, 65, 397-402. | 2.2 | 8 |
| 288 | Chest radiography for general practitioners: Scope for change?. Clinical Radiology, 1992, 46, 51-54. | 1.1 | 7 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 289 | Computed tomography in blunt abdominal trauma: An analysis of clinical management and radiological findings. <i>Clinical Radiology</i> , 1992, 46, 304-310. | 1.1 | 8 |
| 290 | T1-W DCE-MRI:T1-Weighted Dynamic Contrast-Enhanced MRI. , 0, , 341-364. | | 24 |